General Information of Drug (ID: DM5BV5H)

Drug Name
Daxdilimab
Indication
Disease Entry ICD 11 Status REF
Alopecia areata ED70.2 Phase 2 [1]
Dermatomyositis 4A41.0 Phase 2 [2]
Discoid lupus erythematosus EB51.0 Phase 2 [3]
Lupus nephritis 4A40.0Y Phase 2 [4]
Systemic lupus erythematosus 4A40.0 Phase 2 [5]
Drug Type
Monoclonal antibody
Cross-matching ID
TTD ID
DVG1O0
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukocyte immunoglobulin-like receptor subfamily A member 4 (LILRA4) TT7WTBR LIRA4_HUMAN Not Available [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05368103) A Phase 2A, Open Label, Proof of Concept Trial of Daxdilimab for the Treatment of Moderate To Severe Alopecia Areata. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT05669014) A Phase 2, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Daxdilimab Subcutaneous Injection in Adult Participants With Inadequately Controlled Dermatomyositis or Anti-synthetase Inflammatory Myositis. U.S.National Institutes of Health.
3 ClinicalTrials.gov (NCT05591222) A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Investigate the Efficacy and Safety of Daxdilimab Subcutaneous Injection in Reducing Disease Activity in Adult Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus. U.S.National Institutes of Health.
4 ClinicalTrials.gov (NCT05540665) A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy and Safety of Daxdilimab in Adult Participants With Active Proliferative Lupus Nephritis. U.S.National Institutes of Health.
5 ClinicalTrials.gov (NCT05430854) An Open-Label Extension Study To Evaluate The Long- Term Safety And Tolerability Of Daxdilimab (Hzn-7734) In Subjects With Systemic Lupus Erythematosus. U.S.National Institutes of Health.
6 Emerging drugs for the treatment of alopecia areata. Expert Opin Emerg Drugs. 2022 Dec;27(4):379-387.